Further analysis reveals that AD patients with higher baseline blood levels of CCL17 and IL-10 exhibit a higher response rate to dupilumab, suggesting these 2 molecules could serve as potential biomarkers for assessing dupilumab treatment efficacy in clinical practice. This evidence concerns the gene IL10 and Alzheimer disease.